Biological background and targets

The estrogen receptors ERα (ESR1) and ERβ (ESR2) are ligand-activated transcription factors in the nuclear receptor superfamily. Reference gene resources and curated annotations are essential when selecting capture/detection antibodies and epitope domains:

Ligand chemistry for reference controls (e.g., 17β-estradiol) and potential small-molecule interferents can be checked in federal repositories:

AffiELISA® Rat Estrogen receptor ELISA [ Esr1]

ER ELISA assay formats and epitope strategy

Sandwich ELISA (preferred for ER protein):

  • Capture antibody immobilized to a high-binding plate targets a defined ERα/ERβ epitope (e.g., A/B domain or ligand-binding domain).

  • Detection antibody recognizes a non-overlapping epitope to avoid competition and maximize avidity.

  • Readout via HRP/TMB or AP/PNPP, kinetic or endpoint.

Competitive ELISA (niche use):

  • Useful for limited epitope availability or small-epitope fragments; sensitivity often lower for intact ER protein.

To choose non-overlapping epitopes and avoid cross-reactivity with other keratins, steroid receptors, or splice variants, consult curated domain maps and verified sequences:

  • Protein/gene records and domain features: NCBI Protein

  • MeSH term tree for “Receptors, Estrogen”: NLM MeSH

For general ELISA principles and troubleshooting visuals, university pages are helpful:

Sample types and pre-analytical variables

Common matrices: human/animal serum, plasma (EDTA/heparin), cell lysates, tissue lysates. Key pre-analytical controls:

  • Stabilization: Keep samples on ice, minimize freeze-thaw (≤2).

  • Detergent content: For lysates, non-ionic detergents (e.g., 0.1–1% NP-40/Triton X-100) can improve extraction but may affect antibody binding; validate acceptable ranges.

  • Protease/phosphatase inhibitors: Recommended for nuclear receptor integrity.

  • Hemolysis/lipemia/icterus: Evaluate spectral and matrix interference per bioanalytical guidance.

Authoritative method-validation references and vocabulary:

  • FDA Bioanalytical Method Validation (system suitability, stability, acceptance limits): FDA Guidance

  • Assay design fundamentals: Assay Guidance Manual (NIH/NCBI Bookshelf) AGM

Image générée

Reagents, standards, and calibrators

  • Calibrators: Recombinant ERα and/or ERβ standards with mass verified against a reference; store aliquoted at −80 °C.

  • Matrix-matched standards: Spike calibrators into charcoal-stripped serum or an appropriate surrogate to match binding/viscosity.

  • Controls: At least two independent QC levels (Low/High), preferably three (L/M/H).

  • Traceability: Where possible, reference NIST materials or document traceability chains.

Plate coating, blocking, and binding kinetics

  • Coating concentration: 1–10 µg/mL capture antibody in carbonate buffer, pH 9.6; optimize for dynamic range and minimal background.

  • Blocking: BSA (1–5%), casein, or fish gelatin; titrate to reduce non-specific binding without masking epitopes.

  • Incubation: 60–120 min at RT or 16 h at 4 °C for samples and detection antibody; confirm on-plate association/dissociation kinetics via time-course.

Laboratory safety and handling references:

Detection chemistry and reading parameters

  • HRP/TMB: Measure at 450 nm with 620–650 nm reference; stop solution (e.g., 1 N H₂SO₄) at linear mid-range.

  • AP/PNPP: Measure at 405 nm; slower kinetics but stable signal.

  • Kinetic read can extend dynamic range; ensure linear portion for quantitation.

Instrument method setup guidance and vocabulary standards:

Calibration model, LOD/LOQ, and reportable range

Standard curve models:

  • 4PL or 5PL nonlinear regression; 5PL often fits asymmetry at low/high ends.

  • Weighting (e.g., 1/y or 1/y²) can stabilize residuals across orders of magnitude.

LOD/LOQ (typical definitions):

  • LOD: Mean blank + 3×SDblank (verify matrix-specific).

  • LOQ: Lowest standard with CV ≤20% and RE within ±20%; define a reportable range with back-calculated standards within acceptance.

Regulatory and best-practice references:

Precision, accuracy, recovery, and linearity

Precision:

  • Intra-assay (repeatability): ≥6 replicates per level; target %CV ≤10–15%.

  • Inter-assay (intermediate precision): ≥3 runs/days/operators; target %CV ≤15–20% across levels.

Accuracy/Recovery:

  • Spike-recovery across low/medium/high; target 80–120% recovery unless matrix-specific justification provided.

Linearity/Dilutional parallelism:

  • Serial dilutions (e.g., 1:2 to 1:16) should back-calculate within ±20% of nominal; evaluate parallel slopes vs calibrator curve.

Where to find detailed examples and checklists:

Specificity and cross-reactivity risk management

  • Orthogonal antibodies: Use capture and detection raised in different species/epitope regions (e.g., N-terminal vs LBD).

  • Blocking peptides (epitope-mapped) to verify signal loss when target epitope is pre-occupied.

  • Counter-screening against related nuclear receptors (AR, PR, GR) to rule out cross-binding.

Terminology and indexing terms to design searches:

  • MeSH browser for “Receptors, Androgen/Progesterone/Glucocorticoid”: NLM MeSH

  • Protein domain info and alignments: NCBI Protein

Matrix effects and interference studies

Assess common interferents per matrix:

  • Serum/plasma: high lipid/protein content; heterophilic antibodies; rheumatoid factor.

  • Lysates: detergents, salts, nucleic acids; verify acceptable ranges by spiking studies.

  • Exogenous small molecules: 17β-estradiol and metabolites at supraphysiological levels are not expected to directly bind anti-ER antibodies but can alter receptor conformation; verify via ligand-pretreated lysates and heat-denaturation controls.

Useful federal chemistry/tox endpoints:

  • Estradiol physchem data: PubChem

  • Endocrine disruption background: EPA

Controls, acceptance criteria, and run validity

Minimum recommended controls for each plate/run:

  • Blank (substrate only).

  • Zero (matrix without analyte).

  • Calibrators (≥6 levels across full range).

  • QCs (L/M/H, duplicates).

  • NSB wells (no primary or no secondary) to quantify non-specific binding.

Run acceptance examples (align to internal SOPs and FDA guidance):

  • ≥75% of non-zero standards back-calculate within ±20% (±25% at LLOQ).

  • All QCs within ±20% with %CV ≤20%; at least 2/3 levels passing, including LLOQ QC.

Reference: FDA Bioanalytical Method Validation

Image générée

Data analysis, documentation, and reproducibility

  • Use validated curve-fit algorithms with audit trails; document plate maps, raw OD, background subtraction, weights, and excluded outliers (with rationale).

  • Ensure data/metadata FAIRness and retention per institutional policy: NIH Data Resources

  • Cite accessioned datasets in GEO/PMC when applicable: NCBI GEO, PMC

Troubleshooting quick index

  • High background: Re-optimize blocking (casein vs BSA), shorten incubation, increase wash stringency; verify plate type.

  • Low signal: Confirm antibody activity on positive control lysate; extend incubation; check substrate freshness and reader gains.

  • Poor parallelism: Increase dilution factor for viscous/complex matrices; switch to matrix-matched calibrators.

  • Drift across plate: Use multichannel technique, equilibrate plate to RT; consider automated washer.

Training-style primers and lab basics:

Environmental and occupational considerations

  • Handle acids/bases for stop solutions under appropriate PPE and ventilation (see OSHA): OSHA Laboratory Safety

  • Dispose of chemical/biological waste by institutional policy and local regulations.

  • For potential endocrine-active waste streams, consult EPA guidance: EPA Endocrine Disruption

Example SOP skeleton (copy-adapt for QA)

  1. Scope: Quantitative determination of ERα/ERβ in serum, plasma, and mammalian cell/tissue lysates.

  2. References: FDA Guidance, Assay Guidance Manual, NIST SRMs, NCBI Gene ESR1, NCBI Gene ESR2.

  3. Reagents: Capture/detection mAbs (document clone/lot); recombinant ERα/ERβ calibrators; matrix-matched diluent; TMB; stop solution.

  4. Equipment: Calibrated microplate reader (OD 450/620 nm ref), multichannel pipettes, plate washer.

  5. Procedure: Coat → block → add samples/QCs/standards → incubate → wash → detect → read.

  6. Calibration: 8-point curve (serial 1:2), 5PL weighted fit (1/y²).

  7. Acceptance: Standards/QCs within predefined accuracy/precision; blanks/NSB thresholds.

  8. Validation: Precision (repeatability/intermediate), accuracy (recovery), specificity, parallelism, stability (bench, freeze-thaw).

  9. Records: Plate maps, raw OD files, curve fits, deviation logs, CAPA.

  • Primary keywords: estrogen receptor ELISA, ERα ELISA, ERβ ELISA, estrogen receptor alpha beta sandwich ELISA, ER ELISA kit sensitivity, ER ELISA specificity, ER standard curve, ER LOD LOQ, ER spike recovery.

  • Secondary keywords: nuclear receptor ELISA, steroid receptor assay, matrix effects ELISA, dilutional parallelism, intra-assay CV, inter-assay CV, 4PL 5PL curve, TMB substrate, HRP detection.

  • On-page structure: H1 (this title), H2 sections mirroring the subsections above, internal links to related assays (e.g., PR/AR ELISAs), and external authority links (see the .gov/.edu list embedded throughout).

  • Schema: Add Product/HowTo/TechArticle structured data as appropriate.

  • E-A-T signals: Cite NIH/NCBI, FDA, NIST, EPA, CDC, and reputable .edu training pages (already linked).

  • Media: Include a labeled standard curve figure (4PL/5PL), plate layout, and a short troubleshooting table.

Cynthia

LEAVE A REPLY

Please enter your comment!
Please enter your name here